Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, double-blind, placebo-controlled, two-center, pharmacokinetic study evaluating the systemic absorption and safety of OMS201 [ketoprofen/nifedipine] in subjects undergoing ureteroscopic treatment of unilateral ureteral- or renal pelvis-located stones

X
Trial Profile

Phase 1, double-blind, placebo-controlled, two-center, pharmacokinetic study evaluating the systemic absorption and safety of OMS201 [ketoprofen/nifedipine] in subjects undergoing ureteroscopic treatment of unilateral ureteral- or renal pelvis-located stones

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketoprofen/nifedipine (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 May 2010 Actual number of patients (11) added as reported by ClinicalTrials.gov record.
    • 05 May 2010 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov record.
    • 15 Dec 2008 Status changed from recruiting to completed according to a Omeros media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top